Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance

[1]  Yan Tang,et al.  Gαo potentiates estrogen receptor α activity via the ERK signaling pathway. , 2012, The Journal of endocrinology.

[2]  M. Burow,et al.  Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. , 2012, Oncology reports.

[3]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.

[4]  T. Oskarsson,et al.  Extracellular matrix players in metastatic niches , 2012, The EMBO journal.

[5]  L. Hlatky,et al.  BREAKING THE “HARMONY” OF TNF-α SIGNALING FOR CANCER TREATMENT , 2011, Oncogene.

[6]  P. V. van Diest,et al.  Twist contributes to hormone resistance in breast cancer by down-regulating estrogen receptor alpha , 2011, Oncogene.

[7]  Y. Luqmani,et al.  Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). , 2011, International journal of oncology.

[8]  P. Hahnfeldt,et al.  Abstract 386: Breaking the harmony of TNF-α signaling for cancer treatment , 2011 .

[9]  Steven Elliott,et al.  Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2 , 2011, Cancer biology & therapy.

[10]  B. Beckman,et al.  Sphingosine kinase: A promising cancer therapeutic target , 2011, Cancer biology & therapy.

[11]  L. Rhodes,et al.  Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. , 2010, Endocrinology.

[12]  M. Lacey,et al.  Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence , 2010, Breast Cancer Research and Treatment.

[13]  Jiawang Liu,et al.  Novel d-erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics , 2010, Cancer Chemotherapy and Pharmacology.

[14]  M. Burow,et al.  Sphingolipids as Determinants of Apoptosis and Chemoresistance in the MCF-7 Cell Model System , 2009 .

[15]  George Kollias,et al.  The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. , 2009, The Journal of clinical investigation.

[16]  J. Qiu,et al.  Toll-like receptor 9 agonist inhibits ERα-mediated transactivation by activating NF-κB in breast cancer cell lines , 2009 .

[17]  Jiawang Liu,et al.  Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. , 2009, Journal of medicinal chemistry.

[18]  S. Mader,et al.  NF‐κB and estrogen receptor α interactions: Differential function in estrogen receptor‐negative and ‐positive hormone‐independent breast cancer cells , 2009, Journal of cellular biochemistry.

[19]  Allen P. Miraflor,et al.  Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). , 2009, Endocrinology.

[20]  Yan Tang,et al.  Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype , 2008, Breast Cancer Research.

[21]  Margaret Sutcliffe,et al.  Epithelial–mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis , 2008, Developmental dynamics : an official publication of the American Association of Anatomists.

[22]  H. Nam,et al.  TNF alpha-induced down-regulation of estrogen receptor alpha in MCF-7 breast cancer cells. , 2008, Molecules and cells.

[23]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[24]  S. Badve,et al.  NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2 , 2007, Oncogene.

[25]  S. Chanock,et al.  Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF–LTA) and breast cancer risk , 2007, Human Genetics.

[26]  Lang Li,et al.  Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. , 2006, Cancer research.

[27]  T. Curiel,et al.  Antiestrogenic Glyceollins Suppress Human Breast and Ovarian Carcinoma Tumorigenesis , 2006, Clinical Cancer Research.

[28]  Gema Moreno-Bueno,et al.  Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. , 2006, Cancer research.

[29]  M. Costas,et al.  TNF-α enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B , 2006, Oncogene.

[30]  R. Gaynor,et al.  Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. , 2005, Molecular cell.

[31]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[32]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[33]  J. Massagué,et al.  Epithelial-Mesenchymal Transitions Twist in Development and Metastasis , 2004, Cell.

[34]  Yan Tang,et al.  Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. , 2004, International journal of oncology.

[35]  Yan Tang,et al.  Novel Ceramide Analogs as Potential Chemotherapeutic Agents in Breast Cancer , 2004, Journal of Pharmacology and Experimental Therapeutics.

[36]  Y. Kaneda,et al.  Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. , 2003, Experimental cell research.

[37]  E. Neilson,et al.  The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. , 2003, Cancer research.

[38]  G. Hortobagyi,et al.  Chemotherapy‐Induced Apoptosis and Bcl‐2 Levels Correlate with Breast Cancer Response to Chemotherapy , 2003, Cancer journal.

[39]  H. Nakshatri,et al.  NF-?B and breast cancer , 2002 .

[40]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[41]  M. Nieto,et al.  The snail superfamily of zinc-finger transcription factors , 2002, Nature Reviews Molecular Cell Biology.

[42]  Thomas D. Schmittgen,et al.  Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. , 2000, Analytical biochemistry.

[43]  Debajit K. Biswas,et al.  Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells , 2000 .

[44]  T. Reimer,et al.  Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors , 2000, Histochemistry and Cell Biology.

[45]  A. Giuliano,et al.  Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug‐resistant cancer cells , 1999, Cancer.

[46]  Peter Scheurich,et al.  Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF‐R1 activation by endogenous membrane‐anchored TNF , 1999, The EMBO journal.

[47]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[48]  John Calvin Reed,et al.  Prognostic significance of apoptosis regulators in breast cancer. , 1999, Endocrine-related cancer.

[49]  E. Reddy,et al.  Modulation of life and death by the TNF receptor superfamily , 1998, Oncogene.

[50]  T. Hammond,et al.  Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. , 1998, Cancer research.

[51]  J. Bertin,et al.  Bovine herpesvirus 4 BORFE2 protein inhibits Fas- and tumor necrosis factor receptor 1-induced apoptosis and contains death effector domains shared with other gamma-2 herpesviruses , 1997, Journal of virology.

[52]  G. Sledge,et al.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.

[53]  R. Weichselbaum,et al.  Loss of ceramide production confers resistance to radiation-induced apoptosis. , 1997, Cancer research.

[54]  S. Chouaib,et al.  Alteration of the Sphingomyelin/Ceramide Pathway Is Associated with Resistance of Human Breast Carcinoma MCF7 Cells to Tumor Necrosis Factor-α-mediated Cytotoxicity* , 1997, The Journal of Biological Chemistry.

[55]  M. Hirokawa,et al.  Cell-permeable ceramide inhibits the growth of B lymphoma Raji cells lacking TNF-alpha-receptors by inducing G0/G1 arrest but not apoptosis: a new model for dissecting cell-cycle arrest and apoptosis. , 1996, Leukemia.

[56]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[57]  Seamus J. Martin,et al.  Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.

[58]  B. Spiegelman,et al.  Tumor Necrosis Factor (TNF)-α Inhibits Insulin Signaling through Stimulation of the p55 TNF Receptor and Activation of Sphingomyelinase* , 1996, The Journal of Biological Chemistry.

[59]  A. Seidman,et al.  Chemotherapy for advanced breast cancer: a current perspective. , 1996, Seminars in oncology.

[60]  W. Fiers,et al.  Two tumour necrosis factor receptors: structure and function. , 1995, Trends in cell biology.

[61]  D. Goeddel,et al.  TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40 , 1995, Science.

[62]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[63]  J. Camonis,et al.  Self-association of the Death Domains of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects (*) , 1995, The Journal of Biological Chemistry.

[64]  R. Kerbel,et al.  Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes? , 1994, Journal of cellular biochemistry.

[65]  R. Clarke,et al.  Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. , 1994, Cancer research.

[66]  T. Tursz,et al.  The development of human tumor‐cell resistance to TNF‐α does not confer resistance to cytokine‐induced cellular cytotoxic mechanisms , 1992, International journal of cancer.

[67]  H. Kowarzyk.  Structure and Function. , 1910, Nature.

[68]  M. Lacey,et al.  Tumor necrosis factor receptor 1 functions as a tumor suppressor. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[69]  J. Qiu,et al.  Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines. , 2009, Oncology reports.

[70]  Soon-Cheang Quah,et al.  A Current Perspective , 2007 .

[71]  M. Costas,et al.  TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. , 2006, Oncogene.

[72]  E. D. de Vries,et al.  Death Receptor Ligands, in Particular TRAIL, to Overcome Drug Resistance , 2004, Cancer and Metastasis Reviews.

[73]  H. Pehamberger,et al.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.

[74]  Z. Bebők,et al.  Prognostic relevance of transforming growth factor alpha (TGF-α) and tumor necrosis factor alpha (TNF-α) detected in breast cancer tissues by immunohistochemistry , 2004, Breast Cancer Research and Treatment.

[75]  M. Karin,et al.  NF-kappaB in mammary gland development and breast cancer. , 2003, Journal of mammary gland biology and neoplasia.

[76]  H. Nakshatri,et al.  NF-kappaB and breast cancer. , 2002, Current problems in cancer.

[77]  A. Pardee,et al.  Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[78]  C. Y. Wang,et al.  TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. , 1996, Science.

[79]  D. Green,et al.  Suppression of TNF-alpha-induced apoptosis by NF-kappaB. , 1996, Science.

[80]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. , 1995, Cell.

[81]  P. Németh,et al.  Prognostic relevance of transforming growth factor alpha (TGF-alpha) and tumor necrosis factor alpha (TNF-alpha) detected in breast cancer tissues by immunohistochemistry. , 1994, Breast cancer research and treatment.

[82]  R. Kerbel.  Impact of multicellular resistance on the survival of solid tumors, including micrometastases. , 1994, Invasion & metastasis.

[83]  Kerbel Rs.  Impact of multicellular resistance on the survival of solid tumors, including micrometastases. , 1994 .